ArticleCureus2025
Comparative Efficacy and Cycle-Wise Toxicity of Paclitaxel-Carboplatin Versus Gemcitabine-Cisplatin in Stage IV Non-small Cell Lung Cancer (NSCLC): A Quasi-experimental Study in Bangladesh.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative safety signals of carboplatin and cisplatin in lung cancer: a pharmacovigilance study based on FAERS.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide. In Bangladesh, limited access to novel therapeutics makes platinum-based chemotherapy the mainstay of treatment. This study compares the efficacy and cycle-wise toxicity profiles of paclitaxel-carboplatin versus gemcitabine-cisplatin in Stage IV NSCLC patients. Methods In this quasi-experimental study, 66 Stage IV NSCLC patients at Ahsania Mission Cancer & General Hospital, Dhaka, received paclitaxel-carboplatin (Group A) or gemcitabine-cisplatin (Group B). Tumor response, six- and nine-month survival, and hematologic (e.g., neutropenia, thrombocytopenia) and non-hematologic (e.g., nausea, vomiting) toxicities were assessed over three chemotherapy cycles. Statistical analysis included Chi-square, Mann-Whitney, or t-tests; p < 0.05 was considered significant. Results A partial response was observed in 18 (54.6%) of patients in both groups, with no complete responses recorded. Disease control rates were 26 (78.8%) in Group A and 25 (75.8%) in Group B (p = 0.716). Six-month survival rates were 18 (54.5%) and 20 (60.9%). Nine-month survival rates decreased to 10 (30.3%) and 12 (36.4%), respectively. Group A experienced significantly higher rates of leukopenia and neutropenia across all cycles, with six-cycle incidences of 25 (75.8%) and 26 (78.8%), respectively (p < 0.05). At the same time, thrombocytopenia was notably more common in Group B, with 21 (63.6%) over six cycles (p < 0.05). Non-hematologic toxicities were mild and statistically similar between groups. Conclusions Paclitaxel-carboplatin and gemcitabine-cisplatin demonstrated comparable efficacy and short-term survival. However, their distinct hematologic toxicity profiles highlight the need for individualized regimen selection based on patient tolerance and supportive capacity in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.